, Volume 236, Issue 12, pp 3655–3665 | Cite as

Bupropion increases activation in nucleus accumbens during anticipation of monetary reward

  • Yumiko Ikeda
  • Takuya Funayama
  • Amane Tateno
  • Haruhisa Fukayama
  • Yoshiro Okubo
  • Hidenori SuzukiEmail author
Original Investigation



Bupropion is used for major depressive disorder, smoking cessation aid, and obesity. It blocks reuptake of dopamine and noradrenaline and antagonizes nicotinic acetylcholine receptor. Animal studies showed that bupropion enhanced rewarding effects. In addition, bupropion has the potential to treat patients with reward processing dysfunction. However, neural substrates underlying the bupropion effects on reward function in human subjects are not fully understood.


We investigated single-dose administration of bupropion on neural response of reward anticipation in healthy subjects using a monetary incentive delay (MID) task by functional magnetic resonance imaging (fMRI), especially focusing on nucleus accumbens (NAc) activity to non-drug reward stimuli under bupropion treatment.


We used a randomized placebo-controlled within-subject crossover design. Fifteen healthy adults participated in two series of an fMRI study, taking either placebo or bupropion. The participants performed the MID task during the fMRI scanning. The effects of bupropion on behavioral performance and blood oxygenation level-dependent (BOLD) signal in NAc during anticipation of monetary gain were analyzed.


We found that bupropion significantly increased BOLD responses in NAc during monetary reward anticipation. The increased BOLD responses in NAc were observed with both low and high reward incentive cues. There was no significant difference between placebo and bupropion in behavioral performance.


Our findings provide support for the notion that bupropion enhances non-drug rewarding effects, suggesting a possible mechanism underlying therapeutic effects for patients with motivational deficit.


Bupropion Reward fMRI Nucleus accumbens Monetary incentive delay task 



We are thankful to the Clinical Imaging Center for Healthcare, Nippon Medical School, for their support. In particular, we thank Koji Nagaya, Megumi Hongo, Koji Kanaya, Masaya Suda, and Minoru Sakurai for their technical assistance with the MRI examinations and Michiyo Tamura for research assistance. We also thank Arndt Gerz for his English editing of the manuscript and Brian Knutson and Hidehiko Takahashi for their advice on the MID task.


This study was supported by a Grant-in-Aid for Encouragement of Young Scientists (B) (24791237 to Y.I.) and a grant (S0801035 to H.S.) from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

Compliance with ethical standards

All participants gave written informed consent, and the study was approved by the ethics committee of Nippon Medical School (approval number 223035).

Conflict of interest

The authors declare that they have no conflicts of interest.


The authors are entirely responsible for the scientific content of this paper.

Supplementary material

213_2019_5337_MOESM1_ESM.doc (58 kb)
ESM 1 (DOC 58 kb)
213_2019_5337_MOESM2_ESM.pdf (561 kb)
ESM 2 (PDF 560 kb)


  1. Abler B, Grön G, Hartmann A, Metzger C, Walter M (2012) Modulation of frontostriatal interaction aligns with reduced primary reward processing under serotonergic drugs. J Neurosci 32:1329–1335. CrossRefPubMedPubMedCentralGoogle Scholar
  2. Acheson A, de Wit H (2008) Bupropion improves attention but does not affect impulsive behavior in healthy young adults. Exp Clin Psychopharmacol 16:113–123. CrossRefPubMedPubMedCentralGoogle Scholar
  3. Admon R, Kaiser RH, Dillon DG, Beltzer M, Goer F, Olson DP, Vitaliano G, Pizzagalli DA (2017) Dopaminergic enhancement of striatal response to reward in major depression. Am J Psychiatry 174:378–386. CrossRefPubMedGoogle Scholar
  4. Asari Y, Ikeda Y, Tateno A, Okubo Y, Iijima T, Suzuki H (2018) Acute tramadol enhances brain activity associated with reward anticipation in the nucleus accumbens. Psychopharmacology 235:2631–2642. CrossRefPubMedGoogle Scholar
  5. Aubin HJ, Luquiens A, Berlin I (2014) Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice. Br J Clin Pharmacol 77:324–336. CrossRefPubMedPubMedCentralGoogle Scholar
  6. Balodis IM, Grilo CM, Kober H, Worhunsky PD, White MA, Stevens MC, Pearlson GD, Potenza MN (2014) A pilot study linking reduced fronto-striatal recruitment during reward processing to persistent bingeing following treatment for binge-eating disorder. Int J Eat Disord 47:376–384. CrossRefPubMedGoogle Scholar
  7. Barrett ST, Geary TN, Steiner AN, Bevins RA (2017) Sex differences and the role of dopamine receptors in the reward-enhancing effects of nicotine and bupropion. Psychopharmacology 234:187–198. CrossRefPubMedGoogle Scholar
  8. Beck AT, Steer RA, Brown GK (1996) Manual for the Beck Depression Inventory, 2nd edn. Pearson, TexasGoogle Scholar
  9. Belujon P, Grace AA (2017) Dopamine system dysregulation in major depressive disorders. Int J Neuropsychopharmacol 20:1036–1046. CrossRefPubMedPubMedCentralGoogle Scholar
  10. Benowitz NL, Zhu AZ, Tyndale RF, Dempsey D, Jacob P 3rd (2013) Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. Pharmacogenet Genomics 23:135–141. CrossRefPubMedPubMedCentralGoogle Scholar
  11. Billes SK, Sinnayah P, Cowley MA (2014) Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res 84:1–11. CrossRefPubMedGoogle Scholar
  12. Bischoff S, Bittiger H, Krauss J, Vassout A, Waldmeier P (1984) Affinity changes of rat striatal dopamine receptors in vivo after acute bupropion treatment. Eur J Pharmacol 104:173–176. CrossRefGoogle Scholar
  13. Bond A, Lader M (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47:211–218. CrossRefGoogle Scholar
  14. Bray GA, Frühbeck G, Ryan DH, Wilding JP (2016) Management of obesity. Lancet 387:1947–1956. CrossRefGoogle Scholar
  15. Bruijnzeel AW, Alexander JC, Perez PD, Bauzo-Rodriguez R, Hall G, Klausner R, Guerra V, Zeng H, Igari M, Febo M (2014) Acute nicotine administration increases BOLD fMRI signal in brain regions involved in reward signaling and compulsive drug intake in rats. Int J Neuropsychopharmacol 18:pyu011. CrossRefPubMedPubMedCentralGoogle Scholar
  16. Brunzell DH, McIntosh JM (2012) Alpha7 nicotinic acetylcholine receptors modulate motivation to self-administer nicotine: implications for smoking and schizophrenia. Neuropsychopharmacology 37:1134–1143. CrossRefPubMedGoogle Scholar
  17. Buckholtz JW, Treadway MT, Cowan RL, Woodward ND, Benning SD, Li R, Ansari MS, Baldwin RM, Schwartzman AN, Shelby ES, Smith CE, Cole D, Kessler RM, Zald DH (2010) Mesolimbic dopamine reward system hypersensitivity in individuals with psychopathic traits. Nat Neurosci 13:419–421. CrossRefPubMedPubMedCentralGoogle Scholar
  18. Cheetham SC, Kettle CJ, Martin KF, Heal DJ (1995) D1 receptor binding in rat striatum: modification by various D1 and D2 antagonists, but not by sibutramine hydrochloride, antidepressants or treatments which enhance central dopaminergic function. J Neural Transm Gen Sect 102:35–46. CrossRefPubMedGoogle Scholar
  19. Chevassus H, Farret A, Gagnol JP, Ponçon CA, Costa F, Roux C, Galtier F, Petit P (2013) Psychological and physiological effects of bupropion compared to methylphenidate after prolonged administration in healthy volunteers (NCT00285155). Eur J Clin Pharmacol 69:779–787. CrossRefPubMedGoogle Scholar
  20. Conners CK, Casat CD, Gualtieri CT, Weller E, Reader M, Reiss A, Weller RA, Khayrallah M, Ascher J (1996) Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 35:1314–1321. CrossRefPubMedGoogle Scholar
  21. Cook JW, Piper ME, Leventhal AM, Schlam TR, Fiore MC, Baker TB (2015) Anhedonia as a component of the tobacco withdrawal syndrome. J Abnorm Psychol 124:215–225. CrossRefPubMedGoogle Scholar
  22. Cryan JF, Bruijnzeel AW, Skjei KL, Markou A (2003) Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology 168: 347–358. CrossRefGoogle Scholar
  23. Damaj MI, Carroll FI, Eaton JB, Navarro HA, Blough BE, Mirza S, Lukas RJ, Martin BR (2004) Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol 66:675–682. CrossRefPubMedGoogle Scholar
  24. David SP, Munafò MR, Johansen-Berg H, Smith SM, Rogers RD, Matthews PM, Walton RT (2005) Ventral striatum/nucleus accumbens activation to smoking-related pictorial cues in smokers and nonsmokers: a functional magnetic resonance imaging study. Biol Psychiatry 58:488–494. CrossRefPubMedPubMedCentralGoogle Scholar
  25. Dean Z, Horndasch S, Giannopoulos P, McCabe C (2016) Enhanced neural response to anticipation, effort and consummation of reward and aversion during bupropion treatment. Psychol Med 46:2263–2274. CrossRefPubMedGoogle Scholar
  26. Dhillon S, Yang LP, Curran MP (2008) Bupropion: a review of its use in the management of major depressive disorder. Drugs 68:653–689. CrossRefPubMedGoogle Scholar
  27. Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT (2006) Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 12:178–207. CrossRefPubMedGoogle Scholar
  28. Egerton A, Shotbolt JP, Stokes PR, Hirani E, Ahmad R, Lappin JM, Reeves SJ, Mehta MA, Howes OD, Grasby PM (2010) Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: an [11C]raclopride PET study. Neuroimage 50:260–266. CrossRefPubMedGoogle Scholar
  29. Farr OM, Li CS, Mantzoros CS (2016) Central nervous system regulation of eating: insights from human brain imaging. Metabolism 65:699–713. CrossRefPubMedPubMedCentralGoogle Scholar
  30. Faul F, Erdfelder E, Lang AG, Buchner A (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39:175–191. CrossRefGoogle Scholar
  31. Foulds J, Burke M, Steinberg M, Williams JM, Ziedonis DM (2004) Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs 9:39–53. CrossRefPubMedGoogle Scholar
  32. Fryer JD, Lukas RJ (1999) Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 288:88–92PubMedGoogle Scholar
  33. Funayama T, Ikeda Y, Tateno A, Takahashi H, Okubo Y, Fukayama H, Suzuki H (2014) Modafinil augments brain activation associated with reward anticipation in the nucleus accumbens. Psychopharmacology 231:3217–3228. CrossRefPubMedGoogle Scholar
  34. George TP, O’Malley SS (2004) Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci 25:42–48. CrossRefPubMedGoogle Scholar
  35. Gobbi G, Slater S, Boucher N, Debonnel G, Blier P (2003) Neurochemical and psychotropic effects of bupropion in healthy male subjects. J Clin Psychopharmacol 23:233–239. CrossRefPubMedGoogle Scholar
  36. Graf H, Metzger CD, Walter M, Abler B (2016) Serotonergic antidepressants decrease hedonic signals but leave learning signals in the nucleus accumbens unaffected. Neuroreport 27:18–22. CrossRefPubMedGoogle Scholar
  37. Hall BJ, Pearson LS, Buccafusco JJ (2010) Effect of administration of the nicotinic acetylcholine receptor antagonist BTMPS, during nicotine self-administration, on lever responding induced by context long after withdrawal. Neuropharmacology 58:429–435. CrossRefPubMedGoogle Scholar
  38. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55. CrossRefPubMedGoogle Scholar
  39. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62. CrossRefPubMedPubMedCentralGoogle Scholar
  40. Hamilton MJ, Bush M, Smith P, Peck AW (1982) The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man. Br J Clin Pharmacol 14:791–797. CrossRefPubMedPubMedCentralGoogle Scholar
  41. Herrera-Guzmán I, Gudayol-Ferré E, Lira-Mandujano J, Herrera-Abarca J, Herrera-Guzmán D, Montoya-Pérez K, Guardia-Olmos J (2008) Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder. Psychiatry Res 160:72–82. CrossRefPubMedGoogle Scholar
  42. Höflich A, Michenthaler P, Kasper S, Lanzenberger R (2019) Circuit mechanisms of reward, anhedonia, and depression. Int J Neuropsychopharmacol 22:105–118. CrossRefPubMedGoogle Scholar
  43. Høiseth G, Haslemo T, Uthus LH, Molden E (2015) Effect of CYP2B6*6 on steady-state serum concentrations of bupropion and hydroxybupropion in psychiatric patients: a study based on therapeutic drug monitoring data. Ther Drug Monit 37:589–593. CrossRefPubMedGoogle Scholar
  44. Jasmin L, Narasaiah M, Tien D (2006) Noradrenaline is necessary for the hedonic properties of addictive drugs. Vasc Pharmacol 45:243–250. CrossRefGoogle Scholar
  45. Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540–545. CrossRefGoogle Scholar
  46. Kim W, Tateno A, Arakawa R, Sakayori T, Ikeda Y, Suzuki H, Okubo Y (2014) In vivo activity of modafinil on dopamine transporter measured with positron emission tomography and [18F]FE-PE2I. Int J Neuropsychopharmacol 17:697–703. CrossRefPubMedGoogle Scholar
  47. Knutson B, Adams CM, Fong GW, Hommer D (2001) Anticipation of increasing monetary reward selectively recruits nucleus accumbens. J Neurosci 21:RC159. CrossRefPubMedPubMedCentralGoogle Scholar
  48. Knutson B, Bhanji JP, Cooney RE, Atlas LY, Gotlib IH (2008) Neural responses to monetary incentives in major depression. Biol Psychiatry 63:686–692. CrossRefPubMedGoogle Scholar
  49. Kroemer NB, Small DM (2016) Fuel not fun: reinterpreting attenuated brain responses to reward in obesity. Physiol Behav 162:37–45. CrossRefPubMedPubMedCentralGoogle Scholar
  50. Learned-Coughlin SM, Bergström M, Savitcheva I, Ascher J, Schmith VD, Långstrom B (2003) In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry 54:800–805. CrossRefGoogle Scholar
  51. Li SX, Perry KW, Wong DT (2002) Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats. Neuropharmacology 42:181–190. CrossRefGoogle Scholar
  52. Ma H, Zhang W, Yang X, Zhang Y, Wei S, Zhang H, Ma Y, Dang H (2018) Effects of genetic polymorphisms of CYP2B6 on the pharmacokinetics of bupropion and hydroxybupropion in healthy Chinese subjects. Med Sci Monit 24:2158–2163. CrossRefPubMedPubMedCentralGoogle Scholar
  53. Mansvelder HD, Fagen ZM, Chang B, Mitchum R, McGehee DS (2007) Bupropion inhibits the cellular effects of nicotine in the ventral tegmental area. Biochem Pharmacol 74:1283–1291. CrossRefPubMedPubMedCentralGoogle Scholar
  54. Martin KF, Phillips I, Cheetham SC, Heal DJ (1995) Dopamine D2 receptors: a potential pharmacological target for nomifensine and tranylcypromine but not other antidepressant treatments. Pharmacol Biochem Behav 51:565–569. CrossRefGoogle Scholar
  55. McNair DM, Lorr M, Droppleman LF (1971) Manual for the Profile of Mood States. Educational and Industrial Testing Service, CaliforniaGoogle Scholar
  56. Mooney ME, Sofuoglu M (2006) Bupropion for the treatment of nicotine withdrawal and craving. Expert Rev Neurother 6:965–981. CrossRefPubMedGoogle Scholar
  57. Mori T, Shibasaki M, Ogawa Y, Hokazono M, Wang TC, Rahmadi M, Suzuki T (2013) Comparison of the behavioral effects of bupropion and psychostimulants. Eur J Pharmacol 718:370–375. CrossRefPubMedGoogle Scholar
  58. Oldfield RC (1971) The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 9:97–113. CrossRefGoogle Scholar
  59. Oldham S, Murawski C, Fornito A, Youssef G, Yücel M, Lorenzetti V (2018) The anticipation and outcome phases of reward and loss processing: a neuroimaging meta-analysis of the monetary incentive delay task. Hum Brain Mapp 39:3398–3418. CrossRefPubMedPubMedCentralGoogle Scholar
  60. Ossewaarde L, Verkes RJ, Hermans EJ, Kooijman SC, Urner M, Tendolkar I, van Wingen GA, Fernández G (2011) Two-week administration of the combined serotonin-noradrenaline reuptake inhibitor duloxetine augments functioning of mesolimbic incentive processing circuits. Biol Psychiatry 70:568–574. CrossRefPubMedGoogle Scholar
  61. Palmatier MI, Levin ME, Mays KL, Donny EC, Caggiula AR, Sved AF (2009) Bupropion and nicotine enhance responding for nondrug reinforcers via dissociable pharmacological mechanisms in rats. Psychopharmacology 207:381–390. CrossRefPubMedPubMedCentralGoogle Scholar
  62. Patel K, Allen S, Haque MN, Angelescu I, Baumeister D, Tracy DK (2016) Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Ther Adv Psychopharmacol 6:99–144. CrossRefPubMedPubMedCentralGoogle Scholar
  63. Paterson NE, Balfour DJ, Markou A (2007) Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell. Eur J Neurosci 25:3099–3108. CrossRefPubMedGoogle Scholar
  64. Peters J, Bromberg U, Schneider S, Brassen S, Menz M, Banaschewski T, Conrod PJ, Flor H, Gallinat J, Garavan H, Heinz A, Itterman B, Lathrop M, Martinot JL, Paus T, Poline JB, Robbins TW, Rietschel M, Smolka M, Ströhle A, Struve M, Loth E, Schumann G, Büchel C, IMAGEN Consortium (2011) Lower ventral striatal activation during reward anticipation in adolescent smokers. Am J Psychiatry 168:540–549. CrossRefPubMedGoogle Scholar
  65. Pizzagalli DA, Holmes AJ, Dillon DG, Goetz EL, Birk JL, Bogdan R, Dougherty DD, Iosifescu DV, Rauch SL, Fava M (2009) Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. Am J Psychiatry 166:702–710. CrossRefPubMedPubMedCentralGoogle Scholar
  66. Pujol CN, Paasche C, Laprevote V, Trojak B, Vidailhet P, Bacon E, Lalanne L (2018) Cognitive effects of labeled addictolytic medications. Prog Neuro-Psychopharmacol Biol Psychiatry 81:306–332. CrossRefGoogle Scholar
  67. Rahman S, Neugebauer NM, Zhang Z, Crooks PA, Dwoskin LP, Bardo MT (2008) The novel nicotinic receptor antagonist N,N’-dodecane-1,12-diyl-bis-3-picolinium dibromide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens. Eur J Pharmacol 601:103–105. CrossRefGoogle Scholar
  68. Randall PA, Lee CA, Podurgiel SJ, Hart E, Yohn SE, Jones M, Rowland M, López-Cruz L, Correa M, Salamone JD (2014) Bupropion increases selection of high effort activity in rats tested on a progressive ratio/chow feeding choice procedure: implications for treatment of effort-related motivational symptoms. Int J Neuropsychopharmacol 18:pyu017. CrossRefPubMedGoogle Scholar
  69. Rau KS, Birdsall E, Hanson JE, Johnson-Davis KL, Carroll FI, Wilkins DG, Gibb JW, Hanson GR, Fleckenstein AE (2005) Bupropion increases striatal vesicular monoamine transport. Neuropharmacology 49:820–830. CrossRefPubMedGoogle Scholar
  70. Sagara H, Kitamura Y, Yae T, Shibata K, Suemaru K, Sendo T, Araki H, Gomita Y (2008) Nicotinic acetylcholine α4β2 receptor regulates the motivational effect of intracranial self stimulation behavior in the runway method. J Pharmacol Sci 108:455–461. CrossRefPubMedGoogle Scholar
  71. Saji K, Ikeda Y, Kim W, Shingai Y, Tateno A, Takahashi H, Okubo Y, Fukayama H, Suzuki H (2013) Acute NK1 receptor antagonist administration affects reward incentive anticipation processing in healthy volunteers. Int J Neuropsychopharmacol 16:1461–1471. CrossRefPubMedGoogle Scholar
  72. Sánchez C, Hyttel J (1999) Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 19:467–489. CrossRefPubMedGoogle Scholar
  73. Schott BH, Minuzzi L, Krebs RM, Elmenhorst D, Lang M, Winz OH, Seidenbecher CI, Coenen HH, Heinze HJ, Zilles K, Düzel E, Bauer A (2008) Mesolimbic functional magnetic resonance imaging activations during reward anticipation correlate with reward-related ventral striatal dopamine release. J Neurosci 28:14311–14319. CrossRefPubMedPubMedCentralGoogle Scholar
  74. Sescousse G, Caldú X, Segura B, Dreher JC (2013) Processing of primary and secondary rewards: a quantitative meta-analysis and review of human functional neuroimaging studies. Neurosci Biobehav Rev 37:681–696. CrossRefPubMedGoogle Scholar
  75. Slemmer JE, Martin BR, Damaj MI (2000) Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295:321–327PubMedGoogle Scholar
  76. Spielberger CD (1983) Manual for the State-Trait Anxiety Inventory, STAI-form Y. Consulting Psychologists Press, CaliforniaGoogle Scholar
  77. Sweitzer MM, Donny EC, Hariri AR (2012) Imaging genetics and the neurobiological basis of individual differences in vulnerability to addiction. Drug Alcohol Depend 123(Suppl.1):S59–S71. CrossRefPubMedGoogle Scholar
  78. Takamura M, Okamoto Y, Okada G, Toki S, Yamamoto T, Ichikawa N, Mori A, Minagawa H, Takaishi Y, Fujii Y, Kaichi Y, Akiyama Y, Awai K, Yamawaki S (2017) Patients with major depressive disorder exhibit reduced reward size coding in the striatum. Prog Neuro-Psychopharmacol Biol Psychiatry 79:317–323. CrossRefGoogle Scholar
  79. Talairach J, Tournoux P (1988) Co-planar stereotaxic atlas of the human brain: 3-dimensional proportional system—an approach to cerebral imaging. Thieme Medical Publishers, New YorkGoogle Scholar
  80. Telzer EH (2016) Dopaminergic reward sensitivity can promote adolescent health: a new perspective on the mechanism of ventral striatum activation. Dev Cogn Neurosci 17:57–67. CrossRefPubMedGoogle Scholar
  81. Terry P, Katz JL (1997) Dopaminergic mediation of the discriminative stimulus effects of bupropion in rats. Psychopharmacology 134:201–212. CrossRefPubMedGoogle Scholar
  82. Tobey KM, Walentiny DM, Wiley JL, Carroll FI, Damaj MI, Azar MR, Koob GF, George O, Harris LS, Vann RE (2012) Effects of the specific α4β2 nAChR antagonist, 2-fluoro-3-(4-nitrophenyl) deschloroepibatidine, on nicotine reward-related behaviors in rats and mice. Psychopharmacology 223:159–168. CrossRefPubMedPubMedCentralGoogle Scholar
  83. Verdejo-Román J, Vilar-López R, Navas JF, Soriano-Mas C, Verdejo-García A (2017) Brain reward system’s alterations in response to food and monetary stimuli in overweight and obese individuals. Hum Brain Mapp 38:666–677. CrossRefPubMedGoogle Scholar
  84. Versace F, Engelmann JM, Deweese MM, Robinson JD, Green CE, Lam CY, Minnix JA, Karam-Hage MA, Wetter DW, Schembre SM, Cinciripini PM (2017) Beyond cue reactivity: non-drug-related motivationally relevant stimuli are necessary to understand reactivity to drug-related cues. Nicotine Tob Res 19:663–669. CrossRefPubMedPubMedCentralGoogle Scholar
  85. Volkow ND, Morales M (2015) The brain on drugs: from reward to addiction. Cell 162:712–725. CrossRefPubMedGoogle Scholar
  86. Walsh AEL, Browning M, Drevets WC, Furey M, Harmer CJ (2018) Dissociable temporal effects of bupropion on behavioural measures of emotional and reward processing in depression. Philos Trans R Soc Lond Ser B Biol Sci 373:20170030. CrossRefGoogle Scholar
  87. Weinshenker D, Schroeder JP (2007) There and back again: a tale of norepinephrine and drug addiction. Neuropsychopharmacology 32:1433–1451. CrossRefPubMedGoogle Scholar
  88. Whitton AE, Treadway MT, Pizzagalli DA (2015) Reward processing dysfunction in major depression, bipolar disorder and schizophrenia. Curr Opin Psychiatry 28:7–12. CrossRefPubMedPubMedCentralGoogle Scholar
  89. Wilson RP, Colizzi M, Bossong MG, Allen P, Kempton M; MTAC, Bhattacharyya S (2018) The neural substrate of reward anticipation in health: a meta-analysis of fMRI findings in the monetary incentive delay task. Neuropsychol Rev 28:496–506. CrossRefGoogle Scholar
  90. Zaniewska M, Filip M, Przegalinski E (2015) The involvement of norepinephrine in behaviors related to psychostimulant addiction. Curr Neuropharmacol 13:407–418. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Yumiko Ikeda
    • 1
  • Takuya Funayama
    • 2
  • Amane Tateno
    • 3
  • Haruhisa Fukayama
    • 2
  • Yoshiro Okubo
    • 3
  • Hidenori Suzuki
    • 1
    Email author
  1. 1.Department of Pharmacology, Graduate School of MedicineNippon Medical SchoolTokyoJapan
  2. 2.Anesthesiology and Clinical Physiology, Graduate SchoolTokyo Medical and Dental UniversityTokyoJapan
  3. 3.Department of Neuropsychiatry, Graduate School of MedicineNippon Medical SchoolTokyoJapan

Personalised recommendations